European initiatives for better training in medicines development
Journal Title: Journal of Medicines Development Sciences - Year 2015, Vol 1, Issue 1
Abstract
In the last decade, the environment for medicines development has undergone unprecedented change, including: a shift from predominantly big Pharma to one of extensive industry–academia and SME partnerships and collaborations, greater emphasis on understanding the molecular basis of disease for stratified and personalised medicine, and a focus on societal/patients’ needs and priorities. A variety of European initiatives have been established to support the training of scientists/professionals involved in medicines development in order to respond to this constantly changing, demanding, and chaotic landscape. Some of these initiatives are directed specifically at medicines development, some address scientific research including training relevant to medicines development, and some support general training needs which can include medicines development. There are a number of European initiatives supporting better training in medicines development. They differ in their approach, ranging from IMI (specific to medicines development) to Erasmus+ (boosting skills and employability in all areas). The scope, budgets, and requirements differ considerably and they each have to be reviewed in detail to decide which might be the most appropriate for a particular target group. The common theme is to support the aims of the European Research Area (ERA), i.e., a significant improvement in Europe’s research performance to promote growth and job creation.
Authors and Affiliations
Mike Hardman
Keywords
Related Articles
- EP ID EP679262
- DOI -
- Views 143
- Downloads 0
Competencies: A new currency for continuing professional development
“No research without trained researchers” has become the mantra of the EU-funded Innovative Medicines Initiative (IMI) education and training projects. However, it is often hard to determine the type of training required...
Role of the P2Y6 receptor of UDP in the modulation of murine dendritic cell functions and Th1 polarisation of the immune response
Numerous studies have demonstrated the role of uridine diphosphate (UDP) and its P2Y6 receptor in the inflammatory reaction and innate immunity. However, the importance of the P2Y6 receptor in the adaptive immune respons...
Investigative safety strategies to improve success in drug development
Understanding and reducing attrition rate remains a key challenge in drug development. Preclinical and clinical safety issues still represent about 40% of drug discontinuation, of which cardiac and liver toxicities are t...
The Association for the Accreditation of Human Research Protection Programs: 15 years of emphasizing research safety, ethics, and quality
This year marks the 15th anniversary of the founding of the Association for the Accreditation of Human Research Protection Programs (AAHRPP), an organization that has been instrumental in strengthening protections for re...
Critical Path to Tuberculosis Drug Regimens: Global collaboration to accelerate development of novel drug regimens and rapid drug susceptibility tests for tuberculosis
The Critical Path to Tuberculosis Drug Regimens (CPTR) initiative aims to support the rational deployment of new tuberculosis (TB) therapies by speeding the development and impact of new and markedly improved drug regime...